Hospital at home: which startup is ahead?
In our digital health market deck, you will find everything you need to understand the market
SUMMARY
DispatchHealth is currently the startup ahead in hospital at home, with the broadest delivery network, the most complete product, and the clearest ability to run complex care outside the hospital.
The comparison is not entirely straightforward because these startups sell three different things. DispatchHealth and myLaurel deliver much of the care themselves, Current Health and Doccla help hospitals operate their own programs, while Reimagine Care and MedArrive focus on narrower parts of the workflow.
The market looks larger on paper than it does in practice. Hundreds of American hospitals have received approval to provide acute care at home, but meaningful admission volume remains concentrated among a small number of experienced programs.
DispatchHealth’s main advantage is physical infrastructure, not simply software. Its clinicians, mobile imaging, laboratory capabilities, payer relationships, logistics, and local operating density are difficult to reproduce market by market.
Doccla ranks second because it has reached exceptional institutional scale across European public healthcare systems. Its more than four million monitored patient-days are impressive, although European virtual wards cover a broader range of acuity than American inpatient-level hospital-at-home programs.
Current Health remains the strongest independent technology platform. Its clinical pathways, command-center tools, deterioration detection, virtual support, and Cardinal Health logistics partnership make it the best fit for hospitals that want to retain control of care delivery.
myLaurel is the fastest-moving challenger. Its recent patient, partner, and facility growth is far ahead of the field, and its Ochsner results provide one of the clearest combinations of released bed capacity, lower patient costs, and improved clinical outcomes.
The clinical evidence currently supports hospital at home as a care model more strongly than it supports any particular startup. No independent study has compared the leading vendors head to head, so company outcome claims still need to be interpreted carefully.
The economics are also more nuanced than a simple claim that home hospitalization is cheaper. Recent independent evidence suggests that the acute stay itself can cost more, while savings appear later through lower post-discharge spending, fewer avoidable visits, and released hospital capacity.
Our final ranking places DispatchHealth first, Doccla second, Current Health narrowly third, and myLaurel fourth. Reimagine Care has the strongest specialist position, while MedArrive remains an interesting operational challenger and SENA Health lacks enough public data to rank higher.
This market map, featured in our digital health market deck, highlights top companies and startups in the digital health market
Which hospital-at-home startups are worth comparing?
The serious hospital-at-home field currently contains seven startups, but they compete through three different models: direct care, hospital infrastructure, and specialist care.
DispatchHealth and myLaurel send clinicians into the home and take responsibility for a large part of the care itself. Doccla and Current Health mainly give hospitals the monitoring, software, clinical support, devices, and logistics needed to run their own programs. MedArrive focuses on moving patients and field teams through the system efficiently. Reimagine Care has built a narrower virtual oncology service, while SENA Health remains a smaller regional operator.
We exclude remote-monitoring vendors that only touch hospital at home occasionally. We also leave out Contessa Health because it belongs to Amedisys, and Inbound Health because it closed before MedArrive bought selected technology assets. Axle Health is relevant to home-care logistics, but its customer base extends far beyond inpatient-level care at home, so we treat it as an adjacent company rather than a direct contender.
Funding figures are less clean than they look. Databases disagree over debt, undisclosed rounds, predecessor companies, and capital raised before acquisitions. We use the clearest currently available totals and avoid combining myLaurel with all the money previously raised by Ready Responders. Tracxn reports about $700 million for DispatchHealth, $79.1 million for Current Health, $70.9 million for Doccla, $70.3 million for MedArrive, and $27.4 million for Reimagine Care. DispatchHealth’s effective capital base is larger because Medically Home had separately raised about $197 million before the merger. myLaurel has disclosed $12 million under the current company, while SENA has announced seed financing without publishing the amount.
| Startup | Main model | What it sells | Publicly reported funding |
|---|---|---|---|
| DispatchHealth | Direct care plus infrastructure | Same-day, inpatient-level, and transitional care delivered at home | About $700M, plus roughly $197M previously raised by Medically Home |
| Current Health | Hospital infrastructure | Monitoring, clinical pathways, virtual nursing, command-center tools, and logistics | About $79M |
| Doccla | Managed virtual wards | Devices, software, monitoring, logistics, and pathway support | About $71M |
| MedArrive | Home-care operations software | Patient navigation, scheduling, routing, and field-workforce management | About $70M |
| Reimagine Care | Specialist virtual care | AI-supported oncology symptom management and clinical escalation | About $27M |
| myLaurel | Direct acute and transitional care | In-home clinicians, diagnostics, treatment, and virtual physician oversight | $12M disclosed under the current company |
| SENA Health | Regional care delivery and enablement | Staffing, coordination, monitoring, and program support | Undisclosed seed funding |
Is there a clear hospital-at-home leader now?
DispatchHealth is currently ahead overall, although Doccla leads European virtual wards and Current Health remains the strongest independent technology platform in the United States.
The market has moved beyond the experimental stage, but most approved programs are still small. The American Hospital Association counted 419 approved hospitals across 147 systems and 39 states by September 2025. A large JAMA Network Open study published more recently could only include 68 hospitals with at least 12 hospital-at-home admissions, and just 11 hospitals produced about half of all admissions in the dataset. Approval has spread much faster than meaningful patient volume.
DispatchHealth can handle more of the physical care itself, with more than 50 enterprise customers across over 20 states after combining with Medically Home. Doccla has much deeper penetration inside European public health systems. Current Health fits hospitals that want to keep their own clinicians and buy the technology, protocols, monitoring, and support around them.
If you want more recent data on this point, please see our latest digital health market report.
As this chart shows, and as featured in our digital health market deck, search interest in longevity apps and related topics has been increasing
Who has the strongest commercial traction?
DispatchHealth has the strongest broad commercial traction, while Doccla has the largest published monitoring footprint and Current Health shows the clearest scale among independent hospital-at-home platforms.
DispatchHealth says it has treated 1.2 million people across its wider home-care business and now serves the largest enterprise customer base in this comparison. The 1.2 million figure includes same-day and transitional care, so we cannot present it as hospital-at-home admissions. Even with that limitation, the customer count, geographic reach, mobile imaging, laboratory capability, and payer access put the company well ahead of smaller direct-care providers.
Doccla reports more than four million monitored patient-days and coverage across over 60% of NHS England, as well as programs in Ireland, Scotland, and Wales. Patient-days are not admissions, and many of those pathways sit below full inpatient acuity. Still, four million patient-days do not come from a few publicity pilots. Doccla has become part of day-to-day care delivery across a large public system.
Current Health says its experience now covers more than 34,000 patients across over 40 acute and post-acute programs. At Mass General Brigham, the home-hospital program saved more than 25,000 bed-days across 72 communities. myLaurel is smaller, but its Ochsner partnership has released roughly 15 beds every day for two years.
Reimagine Care says its latest oncology platform has supported more than 10,000 patients. MedArrive has begun rolling out its logistics platform with ChristianaCare, while SENA continues to work through regional health-system partnerships but publishes little comparable volume data.
| Startup | Best disclosed traction measure | What it tells us | Main caveat |
|---|---|---|---|
| DispatchHealth | 50+ enterprise customers | Broadest full-service commercial footprint | Its 1.2M patients include services outside hospital at home |
| Doccla | 4M+ monitored patient-days and 60%+ NHS England coverage | Largest published virtual-ward footprint | Patient-days include different acuity levels |
| Current Health | 34,000+ patients across 40+ acute and post-acute programs | Mature technology operating across several care models | The total is broader than inpatient-equivalent care |
| myLaurel | Large, sustained bed-capacity gain at Ochsner | Real operational value from a direct-care program | Most visible results come from one health system |
| Reimagine Care | 10,000+ oncology patients supported | Meaningful specialist adoption | It does not run general hospital wards at home |
| MedArrive | First major logistics-platform deployment with ChristianaCare | A real health-system implementation | Scale remains largely undisclosed |
| SENA Health | Active regional health-system partnerships | The model works in practice | Public volume is too limited for a strong comparison |
Which hospital-at-home startup is growing fastest lately?
myLaurel is growing fastest lately, and the gap between its reported growth rate and everyone else’s is large.
The company reported a 575% rise in patients served during 2025, a 400% increase in health-system partners, and fivefold growth in facilities. Patient volume therefore reached 6.75 times the previous year’s level while both the customer base and physical footprint expanded at roughly five times. Three related measures moved together, which makes the growth claim more useful than a single percentage attached to an unclear denominator.
Current Health has also shown sharp growth inside a major account. Mass General Brigham expanded its program by 200% in 15 months. Growing that quickly inside one health system shows the product can scale, although it tells us little about Current Health’s whole business. Doccla keeps adding regional public-sector deployments, but it has not published a recent company-wide growth rate that we can compare cleanly.
DispatchHealth is now focused on integrating a much larger organization. Its recent updates discuss leadership, operations, and company-wide integration more than patient growth. That may be sensible after a major combination, but it gives us less proof of acceleration than myLaurel’s patient, partner, and facility numbers.
myLaurel remains much smaller, though. Its growth makes it the fastest mover rather than the scale leader.
This chart, featured in our digital health market deck, shows annual VC investment in digital health startups
Who has the most mature hospital-at-home product?
DispatchHealth has the most mature end-to-end product because it can provide the software, the command structure, the logistics, and the clinicians who enter the home.
Its current offer covers same-day emergency alternatives, inpatient-level hospital alternatives, and transitional care. A health system can ask DispatchHealth to deliver the care, supply the technology, or split the work. It also brings mobile imaging and a moderately complex mobile laboratory, so hospitals need fewer outside vendors during a high-acuity episode.
Current Health has the strongest independent technology stack. It offers more than 50 diagnosis-specific pathways, automated deterioration detection, 24/7 clinical support, a command center, and configurable monitoring. Its recent partnership with Cardinal Health’s Velocare adds delivery, installation, retrieval, and nationwide kit logistics. Hospitals still need to supply much of the physical clinical care, but the product now covers more of the operational work around it.
Doccla is similarly mature for virtual wards. It handles devices, onboarding, monitoring, logistics, and integration while the health system usually retains clinical responsibility. myLaurel sits closer to DispatchHealth because it sends medical teams into the home, although its geographic reach and range of care pathways remain narrower.
For a hospital that wants a turnkey clinical partner, DispatchHealth is ahead. For one that wants to operate the program itself, Current Health and Doccla are more natural fits.
If you want more recent data on this point, please see our latest digital health market report.
Which startup has the best clinical evidence?
No startup can honestly claim the best clinical outcomes today because no independent study has compared these companies head to head.
The strongest current research validates the care model rather than a vendor. A JAMA Network Open analysis matched 4,174 hospital-at-home admissions with 11,697 traditional admissions. Home patients had lower in-hospital mortality, at 0.4% versus 3.6%, and slightly lower emergency-department use within 30 days, at 8.8% versus 10.0%. Thirty-day readmissions were statistically similar. A very recent JAMA analysis of acute heart-failure care also found no significant difference in 30-day or 60-day readmission, escalation, or mortality between selected home and hospital patients.
Among the startups, myLaurel has the strongest new direct-care results. Ochsner reports a 60% relative reduction in readmissions, 85% of enrolled patients completing care at home, and a patient Net Promoter Score of 98 over a two-year partnership. The analysis comes from the partners rather than an independent randomized trial, so we should treat the size of the effect with care. It is still a substantial real-world result across four Ochsner campuses.
Reimagine Care has the best specialist dataset. An outcomes analysis conducted with actuarial firm Accorded compared 2,344 cancer patients with national claims benchmarks and found 68.6% fewer avoidable emergency visits over 180 days. The reduction reached 77.1% among Medicare patients and 45.7% for short hospital stays originating in the emergency department. A claims-based comparison carries more weight than a testimonial, although the study remains observational and company-sponsored.
DispatchHealth publishes broad outcomes including an 8.5% 30-day readmission rate, 58% emergency-room avoidance, and 98% patient satisfaction across its wider business. Those numbers cover several service lines, which makes them less useful for isolating inpatient-level care. We give DispatchHealth the strongest operating history, myLaurel the strongest recent direct-care study, and Reimagine Care the best evidence inside a specialty.
This chart, featured in our digital health market deck, shows how Hinge Health captured share in digital health
Which startup offers the best economics?
myLaurel currently gives hospitals the clearest financial case, while DispatchHealth probably has the strongest economics in markets where it can keep its teams busy.
The Ochsner program saved more than 10,500 bed-days. The same two-year review reported a 30% reduction in patient costs, and myLaurel says it puts part of its fees at risk. That combination is unusually concrete: released capacity for the hospital, lower costs for patients, and a vendor that only earns its full fee when results arrive. The missing piece is the hospital’s total program cost, which neither party disclosed.
DispatchHealth says its combined model can cut total cost of care by as much as 30% over 30 days. Its local teams can serve same-day, inpatient-level, and transitional cases, giving the company more chances to spread fixed costs across a market. We cannot confirm how many local operations have reached that density because DispatchHealth does not publish revenue or market-level margins.
The latest independent evidence is less dramatic than company marketing. In the large JAMA analysis, hospital-at-home index stays cost about 10% more, while total healthcare costs were 4% lower and post-discharge costs were 35% lower. Home care can save money across the whole episode even when the acute stay itself costs more. The realistic business case rests on lower downstream spending, not an automatically cheaper acute admission.
Current Health and Doccla sell a lighter operating model, but their customers still pay for doctors, nurses, pharmacy, diagnostics, and emergency escalation. Their software may be cheaper than a full-service provider, yet the complete program is only economical when the hospital recruits enough suitable patients.
If you want more recent data on this point, please see our latest digital health market report.
Who can actually scale beyond a few pilots?
DispatchHealth remains the only startup that has clearly scaled both the digital and physical sides of complex home care across many American markets.
The company already operates in more than 20 states and can reuse local teams across three levels of care. A mobile clinician, imaging unit, laboratory capability, payer contract, and dispatch system can support several services rather than sitting idle while a hospital waits for the next eligible inpatient. That shared operating base is the reason the model can scale.
Current Health has found the strongest alternative. Mass General Brigham scaled across 72 communities, while Cardinal Health now handles monitoring-kit delivery, installation, and retrieval for Current Health programs. Outsourcing the last mile removes one of the biggest reasons hospital-at-home programs stall after a successful pilot.
Doccla has shown that software, devices, monitoring, and onboarding can stretch across public systems. Its South West London agreement covers virtual wards and care homes across a population of about 1.5 million and connects several hospitals, local authorities, and community providers. The NHS supplies much of the hands-on workforce, so this proves platform scale more than independent clinical delivery.
myLaurel now has enough growth to be taken seriously, but a fivefold expansion from a small base differs from running a dependable network across dozens of regions. It needs another two or three Ochsner-sized deployments before we can place it beside DispatchHealth on delivery scale.
This chart, featured in our digital health market deck, shows annual funding in digital health startups
Who has won the strongest customers and contracts?
DispatchHealth has the broadest customer base, while Doccla has the deepest visible public-sector contracts and Current Health has the strongest American reference account.
DispatchHealth’s customer base includes health systems, payers, and at-risk provider groups. That mix gives it several referral channels and reduces its dependence on a single hospital’s discharge team. The weakness is disclosure: the company rarely publishes contract values, patient commitments, or renewal rates, so we know the relationships are broad without knowing how large each one is.
Doccla’s NHS relationships look deeper because they cover regions rather than isolated departments. Its South West London contract runs for two years and spans virtual wards, care homes, several provider organizations, and multiple electronic-record systems. Doccla also says it now has live services in every London Integrated Care Board. These are operating contracts inside public infrastructure, not loose partnership announcements.
Current Health’s work with Mass General Brigham remains one of the best proof points in the market. A program that grows 200%, reaches 72 communities, and saves more than 25,000 bed-days has moved far beyond a pilot. Reimagine Care has also turned early oncology projects into deeper relationships, including a multi-year expansion with Memorial Hermann and a Tampa General deployment backed by an investment from the health system’s venture arm.
What can DispatchHealth do that competitors cannot easily copy?
DispatchHealth is hardest to copy because it has already built local clinical operations across many markets.
A competitor can buy connected devices, build a dashboard, and hire a virtual nursing team. Reproducing DispatchHealth’s field network requires licensed clinicians, local scheduling density, mobile imaging, laboratory operations, payer contracts, clinical protocols, and the ability to respond when a patient deteriorates. Each market has to work as a real service business, not only as a software deployment.
Its three care levels strengthen that network. Same-day visits create volume, hospital-level episodes use more complex capabilities, and transitional care keeps teams involved after discharge. This wider funnel makes local operations easier to sustain than a business depending only on a small number of inpatient-equivalent admissions.
Current Health and Doccla have different forms of defensibility. Their products sit inside clinical workflows, collect years of operational data, and connect with hospital records, devices, and escalation protocols. Switching is possible, but it becomes painful once several care pathways and teams depend on the platform. Reimagine Care has an even narrower advantage through oncology-specific pathways, clinician expertise, and data gathered between cancer visits.
If you want more recent data on this point, please see our latest digital health market report.
This chart, featured in our digital health market deck, compares the main business model options for digital health SaaS platforms
Is the best-funded startup using its money well?
The funding leader is also the operating leader, but DispatchHealth has not disclosed enough financial data to prove that it uses capital efficiently.
As shown in the opening table, DispatchHealth raised about $700 million before counting the capital previously put into Medically Home. That combined total is roughly eleven times Current Health’s funding and close to sixty times the $12 million disclosed by the current myLaurel entity. The spending has produced a wide physical footprint and a broader product than any rival. We still lack revenue, cash burn, contribution margins, and profitability by market.
Current Health offers a warning against reading too much into headline valuations. Best Buy acquired the company for about $400 million in 2021, then sold it back to co-founder Christopher McGhee for an undisclosed amount in 2025 after its home-health strategy took longer than expected to pay off. Current Health kept strong technology and customers, but the transaction shows how far enterprise adoption can sit from an attractive financial return.
myLaurel currently looks capital-efficient because its disclosed funding is modest beside its recent growth. We should not overstate that conclusion without revenue and burn data, but it has produced more operating progress per publicly disclosed dollar than the larger field has shown lately.
Who has the strongest momentum today?
DispatchHealth has the strongest strategic momentum today, while myLaurel is expanding fastest and Current Health is staging the most credible comeback.
The biggest change in the market is the extension of the CMS Acute Hospital Care at Home waiver through September 2030. Hospitals can now plan beyond a short congressional deadline, and vendors can sell programs with a realistic multi-year payback period. DispatchHealth benefits most because it has the widest American delivery network ready to absorb new demand.
DispatchHealth also promoted Erin Bartley to president with responsibility for operations, growth, and company-wide integration. That appointment points to the company’s immediate job: turn its combined care-delivery and technology assets into one repeatable system. The integration could still go badly, but policy and management are now pulling in the same direction.
Current Health has regained independence and added Cardinal Health to solve nationwide kit logistics. MedArrive bought Inbound Health’s patient-navigation assets and appointed a new chief executive. Reimagine Care released a more capable version of its oncology assistant. Useful advances, yes, but none changes the overall ranking yet.
This chart, featured in our digital health market deck, shows how revenue is split across customer segments in the digital health market
Is Doccla already the European hospital-at-home leader?
Doccla is clearly the European virtual-ward leader today, although its category is broader than American inpatient-level hospital at home.
American CMS programs keep patients under an inpatient admission and require hospital-level care in the home. European virtual wards can also include early discharge, chronic-condition monitoring, and admission prevention. Doccla’s volumes therefore cannot be compared one for one with American hospital admissions.
Even with that adjustment, Doccla’s position is hard to dispute. It reports more than four million patient-days and coverage across over 60% of NHS England, with additional work in Ireland, Scotland, and Wales. Its published pathway totals include more than 20,000 respiratory bed-days saved, 12,500 in cardiology, and 7,000 in frailty. Those programs show repeated use across different conditions rather than one successful ward.
Doccla’s advantage comes from fitting into public healthcare systems that already employ the doctors, nurses, and community teams. That lets the company scale faster than a provider building a new clinical workforce city by city. The trade-off is less control over the whole patient experience.
We rank Doccla second overall because it leads a large adjacent version of the category and has reached exceptional institutional scale. It would challenge DispatchHealth for first place if it showed the same depth in full inpatient substitution across several countries.
Which specialist startup could own its niche?
Reimagine Care is the strongest specialist player because it has built a real oncology service rather than a generic monitoring layer with cancer branding.
Cancer patients often develop pain, nausea, fever, dehydration, and treatment side effects between appointments. Reimagine Care combines an AI assistant with oncology-trained clinicians who can manage symptoms, escalate serious cases, and keep avoidable problems out of the emergency department.
Its latest platform has supported more than 10,000 patients and hundreds of thousands of interactions. The company says clinicians resolve 95% of patient needs virtually. More convincing is the 2,344-patient analysis described earlier: avoidable emergency visits fell 68.6% against national claims benchmarks, with a 45.7% reduction in short hospital stays that began in the emergency department.
Reimagine Care can build a strong business around the period between oncology appointments, where traditional providers often have poor visibility and patients default to emergency care. Oncology-specific workflows, trained staff, and longitudinal symptom data give it a more defensible position than a broad chatbot.
This chart, featured in our digital health market deck, shows how remote patient monitoring platform technology has evolved over time
Can MedArrive become the operating system for hospital at home?
MedArrive has found a smart hospital-at-home niche, but today it has not proved it can own that niche.
The company moved away from directly providing care and now sells scheduling, routing, workforce management, and patient-navigation tools. ChristianaCare helped develop and became the first major user of the logistics platform. MedArrive also acquired selected Inbound Health assets, adding technology that helps hospitals identify patients who can move from acute care into the home.
The workflow is straightforward. First find the right patient, then choose the correct home program, then send the right clinician at the right time. That sounds obvious, but many hospital-at-home programs struggle with exactly those handoffs. MedArrive is trying to control the operational flow without carrying the cost of employing every care team itself.
The company still publishes little about active health systems, episodes managed, contract sizes, or measured improvements after deployment. Until several hospitals show that MedArrive raised census, reduced travel time, or lowered staffing costs, the business belongs in the promising-challenger group.
Which hospital-at-home startups are actually ahead?
DispatchHealth is ahead overall now, with Doccla a clear second, Current Health narrowly ahead of myLaurel, and a large gap after the top four.
We weighted real care delivery, repeated commercial use, product maturity, ability to scale, customer quality, outcomes, and recent momentum. Funding helped only when it had clearly turned into operations. On a rough comparison where DispatchHealth equals 100, we place Doccla near 75, Current Health near 65, and myLaurel near 60. The five-point gap between Current Health and myLaurel is small enough to reverse: Current Health is more mature, while myLaurel is growing much faster.
DispatchHealth’s lead would shrink if its integrated model proves too expensive or if hospitals increasingly prefer to keep care delivery in-house. Doccla could move into first place by proving full inpatient-level delivery across several national systems. Current Health could close the gap through its new logistics model, while myLaurel needs to repeat its growth and outcomes across several large health systems.
| Rank | Startup | Relative position | Why it ranks here |
|---|---|---|---|
| 1 | DispatchHealth | 100 | Broadest full-service network, strongest delivery capability, most complete product, and best position to benefit from the longer CMS waiver |
| 2 | Doccla | 75 | Clear European virtual-ward leader with exceptional patient-day volume and public-system reach |
| 3 | Current Health | 65 | Most mature independent technology platform, strong Mass General Brigham proof point, and a better logistics model after partnering with Cardinal Health |
| 4 | myLaurel | 60 | Fastest-growing direct-care challenger, with unusually strong recent outcomes and bed-capacity results |
| 5 | Reimagine Care | 40 | Best specialist position, backed by a substantial oncology dataset and a clear clinical use case |
| 6 | MedArrive | 30 | Smart operational strategy and useful acquired technology, but too little deployment evidence |
| 7 | SENA Health | 20 | Credible regional model with limited public data on scale, contracts, funding, and outcomes |
If you want more recent data on this point, please see our latest digital health market report.
In our digital health market deck, we identify pain points entrepreneurs should prioritize
OUR METHODOLOGY
We approached “which startup is ahead?” by breaking the question into the dimensions that most clearly define leadership in hospital at home: commercial traction, recent growth, product maturity, clinical evidence, economics, scalability, customer quality, defensibility, and current momentum.
For each dimension, we reviewed recent operating results, health-system deployments, patient volumes, clinical outcomes, product developments, partnerships, and policy changes. We assessed each piece of evidence according to what it could genuinely demonstrate. Patient volume helped us evaluate adoption, bed-days released showed operational value, and clinical studies helped us assess outcomes.
Because the companies operate different models, we did not force every disclosure into one common metric. A direct-care provider cannot be judged in exactly the same way as a technology platform or a specialist oncology service. We therefore separated delivery scale, platform scale, specialist leadership, product maturity, and recent acceleration.
We also distinguished company-reported results from independent evidence. Company case studies were useful when they included specific patient counts, bed-days, costs, or outcomes, but they were given less weight than independent clinical research. Funding totals were treated carefully because databases differ on debt, predecessor companies, undisclosed rounds, and capital raised before acquisitions.
The final ranking reflects the aggregation of these point-by-point conclusions rather than funding totals, reputation, or one headline number. The relative scores communicate our overall assessment of each company’s position and are not the result of a rigid mathematical formula.
Key sources included the CMS Acute Hospital Care at Home data release and waiver framework, the CMS study of the initiative, the JAMA Network Open comparison of hospital-at-home and traditional inpatient care, and the JAMA analysis of acute heart-failure care at home.
Company-level evidence came from DispatchHealth’s merger and operating disclosures, Doccla’s published platform results, Current Health’s platform disclosures, the Mass General Brigham case study, myLaurel’s recent growth results, the Ochsner and myLaurel partnership review, Reimagine Care’s oncology publications, and MedArrive’s operating-platform materials.
We prioritized sources that provided specific, checkable information about patients, programs, contracts, geographic reach, clinical outcomes, released capacity, product capabilities, and policy changes. We excluded vague partnership announcements, remote-monitoring companies with only occasional hospital-at-home exposure, and disclosures that could not be connected to a meaningful measure of competitive progress.
This chart, featured in our digital health market deck, shows how revenue is distributed by region across Europe, Asia, North America, Africa, and South America in the digital health market
Related blog posts
- Who is ahead in at-home blood testing?
- Which AI doctor startup is leading the race?
- Are hospitals actually using AI today?
